SCHEMBL4673063

SCHEMBL4673063

O=C(O)/C(O)=C/C(=O)c1cc(S(=O)(=O)c2ccc(F)cc2)co1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.36
PTGS2 P35354 1/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
AKR1C3 P42330 1/20 0.36
TSHR P16473 1/20 0.35
HSD11B1 P28845 1/20 0.34
HTR2A P28223 4/20 0.33
HTR2C P28335 4/20 0.33
KCNH2 Q12809 2/20 0.33
NAMPT P43490 2/20 0.33
IKBKB O14920 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
MMP12 P39900 1/20 0.33
MMP13 P45452 1/20 0.33
MMP14 P50281 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673067 1.00 CA2 (0.36) CA2PTGS2AKR1C2AKR1C1AKR1C3
SCHEMBL4673615 0.88 HTR6 (0.40) CA2TSHRALDH1A1POLB
SCHEMBL4673609 0.88 HTR6 (0.40) CA2TSHRALDH1A1POLB
SCHEMBL4676776 0.87 ALDH1A1 (0.42) CA2AKR1C2AKR1C1AKR1C3NAMPT
SCHEMBL4676772 0.87 ALDH1A1 (0.42) CA2AKR1C2AKR1C1AKR1C3NAMPT
SCHEMBL4679023 0.78 PTGS2 (0.38) CA2PTGS2AKR1C2AKR1C1AKR1C3
SCHEMBL4679020 0.78 PTGS2 (0.38) CA2PTGS2AKR1C2AKR1C1AKR1C3
SCHEMBL4671903 0.77 PTGS2 (0.36) PTGS2AKR1C2AKR1C1AKR1C3HTR2A
SCHEMBL4671905 0.77 PTGS2 (0.36) PTGS2AKR1C2AKR1C1AKR1C3HTR2A
SCHEMBL4674481 0.77 HTR2A (0.32) CA2HTR2AHTR2CKCNH2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CA2 2384/4885PTGS2 4586/4885AKR1C2 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.